Mosaic ImmunoEngineering, Inc. is a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. The Company is focused on new product candidates and platforms to expand its pipeline based on a deep understanding of immunotherapies and its license agreements with University of California San Diego.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
28/10/26	$0.1368	-44.99%	607
27/10/26	$0.2487	+38.17%	500
26/10/26	$0.1800	+200.00%	285

Real-time OTC Markets

More quotes

Market Closed - OTC Markets 17:38:13 20/04/2026 +03			5-day change	1st Jan Change
0.3280 ^USD	-.--%		-1.50%	+5.47%

08-14	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-20	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	991K 889K 822K 744K 1.39M 94.36M 1.41M 9.83M 3.91M 49.38M 3.72M 3.64M 157M	P/E 2024	-5.39x	P/E 2025	-3.11x
Enterprise Value	2.65M 2.38M 2.2M 1.99M 3.72M 253M 3.77M 26.31M 10.48M 132M 9.96M 9.75M 420M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	11.32%	Yield 2024 *	-	Yield 2025	-

08-14	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-20	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-15	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-15	Mosaic ImmunoEngineering, Inc. Auditor Raises 'Going Concern' Doubt	CI
11-19	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
19/08/25	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
20/05/25	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
15/04/25	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
15/04/25	Mosaic ImmunoEngineering, Inc. Auditor Raises 'Going Concern' Doubt	CI
20/11/24	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
14/08/24	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
25/07/24	Mosaic ImmunoEngineering, Inc. Announces Resignation of Carlton Johnson from the Board, the Audit Committee and Compensation Committee	CI
14/05/24	Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

29/04/24	Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.	AQ
28/03/24	Mosaic ImmunoEngineering : Termination of Material Agreement - Form 8-K	PU
04/05/23	MOSAIC IMMUNOENGINEERING INC. : Change in Directors or Principal Officers (form 8-K)	AQ
02/03/23	MOSAIC IMMUNOENGINEERING INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
01/11/22	MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ

Mosaic ImmunoEngineering, Inc. Stock

Stocks

CPMV

US61945M1018

Biotechnology & Medical Research

Valuation: Mosaic ImmunoEngineering, Inc.

Chart: Mosaic ImmunoEngineering, Inc.

Latest news: Mosaic ImmunoEngineering, Inc.

Press Releases: Mosaic ImmunoEngineering, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Mosaic ImmunoEngineering, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	-1.50%
Current month	+437.70%
1 month	+437.70%
3 months	-40.36%
6 months	-56.00%
Current year	+5.47%

1 week	0.14	0.33
1 month	0.06	0.33
Current year	0.05	0.75
1 year	0.05	0.89
3 years	0.05	1.13
5 years	0.05	3
10 years	0.05	9.22

Date	Insider	Type	Main position	% Market Cap.
2/18/22 A	Robert Garnick	Others	Founder	0%
2/18/22 A	Steven King	Others	Chief Executive Officer	0%
2/18/22 A	Robert Baffi	Others	Director	0%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MOSAIC IMMUNOENGINEERING, INC.	-.--%	-1.50%	-35.69%	-42.46%	1.8M
WUXI APPTEC CO., LTD.	+0.65%	-3.36%	+36.98%	+60.50%	63.48B
ARGENX SE	+1.76%	+1.27%	+11.82%	+81.21%	54.55B
LONZA GROUP AG	-0.94%	+0.99%	+10.45%	+100.19%	53.59B
IQVIA HOLDINGS INC.	+2.76%	+0.87%	+27.92%	+55.07%	44.75B
BEONE MEDICINES AG	+2.00%	-3.39%	+17.83%	+119.04%	41.62B
REVOLUTION MEDICINES, INC.	+1.34%	-2.86%	+224.43%	+914.08%	39.91B
CELLTRION, INC.	+0.64%	-3.95%	+11.15%	+45.57%	32.47B
GENMAB A/S	+29.06%	+47.63%	+107.12%	+92.73%	26.7B
WUXI BIOLOGICS (CAYMAN) INC.	+3.72%	-6.23%	+26.01%	-2.99%	23.36B
Average	+4.10%	-0.38%	+43.80%	+142.29%	38.04B
Weighted average by Cap.	+3.23%	-0.29%	+48.19%	+161.47%

	2024	2025
Net sales	-	-
Net income	-922K -827K -765K -693K -1.29M -87.81M -1.31M -9.14M -3.64M -45.95M -3.46M -3.39M -146M	-688K -617K -571K -517K -965K -65.51M -977K -6.82M -2.72M -34.28M -2.58M -2.53M -109M
Net Debt	1.48M 1.33M 1.23M 1.11M 2.07M 141M 2.1M 14.65M 5.84M 73.63M 5.54M 5.43M 234M	1.66M 1.49M 1.38M 1.25M 2.33M 158M 2.36M 16.49M 6.57M 82.84M 6.24M 6.11M 263M